IL273484B2 - a33 antibody preparations and methods for using them in radioimmunotherapy - Google Patents

a33 antibody preparations and methods for using them in radioimmunotherapy

Info

Publication number
IL273484B2
IL273484B2 IL273484A IL27348420A IL273484B2 IL 273484 B2 IL273484 B2 IL 273484B2 IL 273484 A IL273484 A IL 273484A IL 27348420 A IL27348420 A IL 27348420A IL 273484 B2 IL273484 B2 IL 273484B2
Authority
IL
Israel
Prior art keywords
radioimmunotherapy
methods
same
antibody compositions
antibody
Prior art date
Application number
IL273484A
Other languages
English (en)
Hebrew (he)
Other versions
IL273484B1 (en
IL273484A (en
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL273484A publication Critical patent/IL273484A/en
Publication of IL273484B1 publication Critical patent/IL273484B1/en
Publication of IL273484B2 publication Critical patent/IL273484B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL273484A 2017-09-23 2020-03-22 a33 antibody preparations and methods for using them in radioimmunotherapy IL273484B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562373P 2017-09-23 2017-09-23
US201762562374P 2017-09-23 2017-09-23
PCT/US2018/052253 WO2019060750A2 (en) 2017-09-23 2018-09-21 A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY

Publications (3)

Publication Number Publication Date
IL273484A IL273484A (en) 2020-05-31
IL273484B1 IL273484B1 (en) 2025-08-01
IL273484B2 true IL273484B2 (en) 2025-12-01

Family

ID=65810903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273484A IL273484B2 (en) 2017-09-23 2020-03-22 a33 antibody preparations and methods for using them in radioimmunotherapy

Country Status (9)

Country Link
US (2) US11555072B2 (enExample)
EP (1) EP3684369A4 (enExample)
JP (3) JP7303802B2 (enExample)
KR (1) KR102783937B1 (enExample)
CN (1) CN111372590A (enExample)
AU (2) AU2018338322B2 (enExample)
CA (1) CA3076611A1 (enExample)
IL (1) IL273484B2 (enExample)
WO (1) WO2019060750A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
US11122038B1 (en) * 2017-05-18 2021-09-14 United Services Automobile Association (Usaa) Methods and systems for authentication of new users
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
EA202191763A1 (ru) 2018-12-21 2022-03-10 Озе Иммьюнотерапьютикс Бифункциональная молекула анти-pd-1/sirp
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN113557245B (zh) 2018-12-21 2022-10-25 Ose免疫疗法公司 人源化的抗人pd-1抗体
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN114341176A (zh) * 2019-04-08 2022-04-12 纪念斯隆凯特琳癌症中心 Cd19抗体及其使用方法
US20230365636A1 (en) 2020-11-16 2023-11-16 Technische Universität München Bioorthogonal reporter gene system
EP4247426A4 (en) * 2020-11-18 2024-10-23 Memorial Sloan Kettering Cancer Center MULTISPECIFIC ANTI-GPA33 ANTIBODIES AND THEIR USES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
JPH07504334A (ja) * 1992-12-10 1995-05-18 セルテック・リミテッド Ａ３３抗原に対するヒト化抗体
EP1073464B1 (en) * 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
JP4088655B2 (ja) * 2004-09-06 2008-05-21 キリンファーマ株式会社 抗ａ３３抗体
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3200819A4 (en) * 2014-09-30 2018-05-16 The Medical College of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
PT3280432T (pt) 2015-04-06 2021-04-22 Subdomain Llc Polipéptidos que contêm domínio de ligação de novo e seus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KING D J ET AL,, PREPARATION AND PRECLINICAL EVALUATION OF HUMANISED A33 IMMUNOCONJUGATES FOR RADIOIMMUNOTHERAPY, 1 December 1995 (1995-12-01) *

Also Published As

Publication number Publication date
JP7303802B2 (ja) 2023-07-05
US20200291112A1 (en) 2020-09-17
KR20200057759A (ko) 2020-05-26
WO2019060750A3 (en) 2019-05-16
IL273484B1 (en) 2025-08-01
CA3076611A1 (en) 2019-03-28
JP2020534017A (ja) 2020-11-26
KR102783937B1 (ko) 2025-03-24
AU2018338322A1 (en) 2020-04-09
AU2025204844A1 (en) 2025-07-17
US11555072B2 (en) 2023-01-17
CN111372590A (zh) 2020-07-03
JP2025061650A (ja) 2025-04-11
WO2019060750A2 (en) 2019-03-28
EP3684369A2 (en) 2020-07-29
IL273484A (en) 2020-05-31
EP3684369A4 (en) 2021-06-23
JP2023138957A (ja) 2023-10-03
AU2018338322B2 (en) 2025-07-17
US20240327511A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
IL273484B2 (en) a33 antibody preparations and methods for using them in radioimmunotherapy
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
ZA202000608B (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
IL265844A (en) Anti-lag-3 antibodies and preparations
IL262176A (en) Anti-tim-3 antibodies and preparations
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL260688A (en) Antibody preparations for ror2 and methods related thereto
IL256621A (en) Carrier-binder preparations and methods for their preparation and use
HUE065174T2 (hu) HLA-alapú módszerek és készítmények, valamint azok felhasználása
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
IL268249A (en) Anti-tryptase antibodies, their preparations and their uses
IL274809A (en) Antibodies against CXCR5 and their preparations and uses
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
GB201617572D0 (en) Use, method, kit, composition and antibodies
GB2564735B (en) Composition and methods and uses relating thereto
IL268568A (en) TRAILshort antibody and methods of use
ZA202000238B (en) Sost antibody pharmaceutical composition and uses thereof
EP3534951A4 (en) ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
EP3270985A4 (en) Polypeptide compositions and methods of using the same
IL272058A (en) Stabilized antibody preparations and methods for their production
HK40024560A (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
GB201703975D0 (en) Composition and methods
GB2577418B (en) Thermoelectric materials and related compositions and methods
HK40030990A (en) Anti-cxcr5 antibodies and compositions and uses thereof